Pfizer’s Yield: A Slow Turning

The forecasts called for fifty-seven cents a share on sixteen-point-eight billion in sales for the last quarter. What Pfizer brought in was sixty-six cents on seventeen-point-six billion. A good harvest, by most measures. But the fields aren’t yielding as abundantly as they once did.








